drugset
drugset / Trial / NCT03880253

Multiple Ascending Dose Study of CTP-692 in Healthy Volunteers

NCT03880253 ↗

Phase 1 Completed 30 enrolled Concert Pharmaceuticals
RandomizedSequentialDouble-blindBasic science

Summary

This study will assess in healthy male and female subjects the safety and pharmacokinetic (PK) profiles of 3 dose levels of CTP-692 following 7 days of dosing.

Timeline

Start
2019-04-10
Primary completion
2019-05-16
Completion
2019-05-16

Drugs

EvaluationDrugModalityDoseRoute
Subject CTP-692 Unknown — —

Indications

No indication recorded.